A Comparison of Two Medicated Creams (Luliconazole and Ciclopirox) for Treating Common Fungal Skin Infections

Effectiveness of Luliconazole Cream Versus Ciclopirox Olamine Cream in the Management of Localized Cutaneous Dermatophytosis: A Randomized Control Trail - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105863

Enrollment

Registered

2026-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Received Ciclopirox olamine 1% cream.: Frequency: The selected topical antifungal cream was applied twice daily.Method: Patients were taught to apply the cream directly onto the affecte

Eligibility

Inclusion criteria

Inclusion criteria: Clinical Diagnosis: Patients presenting with clinical features of localized cutaneous dermatophytosis.Consent: Individuals who provided written informed consent to participate in the trial.

Exclusion criteria

Exclusion criteria: Pregnancy and Lactation: Patients who were currently pregnant or lactating. Drug Allergies: Individuals with known previous allergies to either Ciclopirox olamine or Luliconazole. Concurrent Therapy: Patients currently using systemic antifungal therapy that could interfere with the study results

Design outcomes

Primary

Measure	Time frame
The main efficacy endpoint was a composite measure of clinical and mycological success assessed after four weeks of treatment.Clinical Efficacy (Global Assessment Score): Achievement of a score of 0 (complete resolution) on a 4-point scale evaluating four key symptoms: pruritus, erythema, induration, and scaling.Mycological Cure: Conversion to a negative mycological status, defined as the absence of dermatophyte hyphae on a 10% potassium hydroxide (KOH) mount examination.Timepoint: The main efficacy endpoint was a composite measure of clinical and mycological success assessed after four weeks of treatment.Clinical Efficacy (Global Assessment Score): Achievement of a score of 0 (complete resolution) on a 4-point scale evaluating four key symptoms: pruritus, erythema, induration, and scaling.Mycological Cure: Conversion to a negative mycological status, defined as the absence of dermatophyte hyphae on a 10% potassium hydroxide (KOH) mount examination.	—

Measure

Time frame

The main efficacy endpoint was a composite measure of clinical and mycological success assessed after four weeks of treatment.Clinical Efficacy (Global Assessment Score): Achievement of a score of 0 (complete resolution) on a 4-point scale evaluating four key symptoms: pruritus, erythema, induration, and scaling.Mycological Cure: Conversion to a negative mycological status, defined as the absence of dermatophyte hyphae on a 10% potassium hydroxide (KOH) mount examination.Timepoint: The main efficacy endpoint was a composite measure of clinical and mycological success assessed after four weeks of treatment.Clinical Efficacy (Global Assessment Score): Achievement of a score of 0 (complete resolution) on a 4-point scale evaluating four key symptoms: pruritus, erythema, induration, and scaling.Mycological Cure: Conversion to a negative mycological status, defined as the absence of dermatophyte hyphae on a 10% potassium hydroxide (KOH) mount examination.

—

Secondary

Measure	Time frame
Safety and Tolerability,Symptom-Specific Resolution,Patient-Reported Outcomes,Recurrence PatternsTimepoint:	—

Countries

India

Contacts

Public ContactSai Shiva Ram

Saveetha medical college and hospital,saveetha institute of medical and technical sciences

drvarunrajagopal@gmail.com8610424075

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026